The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma
Abstract
Context: Besides 123 I-metaiodobenzylguanidine (MIBG), positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including 18 F-3,4-dihydroxyphenylalanine (DOPA), 18 F-fluoro-2-deoxy-D-glucose ( 18 F-FDG), and 18 F-fluorodopamine ( 18 F-FDA).Objective: The objective of the study was to establish the optimal approach to the functional imaging of PGL and examine the link between genotype-specific tumor biology and imaging. Design: This was a prospective observational study.Intervention: There were no interventions.Patients: Fifty-two patients (28 males, 24 females, aged 46.8 Ϯ 14.2 yr): 20 with nonmetastatic PGL (11 adrenal), 28 with metastatic PGL (13 adrenal), and four in whom PGL was ruled out; 22 PGLs were of the succinate dehydrogenase subunit B (SDHB) genotype.Main Outcome Measures: Sensitivity of 18 F-DOPA, 18 F-FDG, and 18 F-FDA PET, 123 I-MIBG scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) for the localization of PGL were measured.Results: Sensitivities for localizing nonmetastatic PGL were 100% for CT and/or MRI, 81% for 18 F-DOPA PET, 88% for 18 F-FDG PET/CT, 78% for 18 F-FDA PET/CT, and 78% for 123 I-MIBG scintigraphy.For metastatic PGL, sensitivity in reference to CT/MRI was 45% for 18 F-DOPA PET, 74% for 18 F-FDG PET/CT, 76% for 18 F-FDA PET/CT, and 57% for 123 I-MIBG scintigraphy.In patients with SDHB metastatic PGL, 18 F-FDA and 18 F-FDG have a higher sensitivity (82 and 83%) than 123 I-MIBG (57%) and 18 F-DOPA (20%).Conclusions: 18 F-FDA PET/CT is the preferred technique for the localization of the primary PGL and to rule out metastases.Second best, equal alternatives are 18 F-DOPA PET and 123 I-MIBG scintigraphy.For patients with known metastatic PGL, we recommend 18 F-FDA PET in patients with an unknown genotype, 18 F-FDG or 18 F-FDA PET in SDHB mutation carriers, and 18 F-DOPA or 18 F-FDA PET in non-SDHB patients.(J Clin Endocrinol Metab 94: 4757-4767, 2009) P aragangliomas (PGLs) derive from sympathetic chro- maffin tissue in adrenal and extraadrenal abdominal or thoracic locations or from parasympathetic tissue of the head and neck (1).The terms pheochromocytoma and glomus tumor refer to respective adrenal PGL and head and neck PGL (2, 3).The majority of abdominal and thoracic PGLs produce catecholamines (4), whereas head and neck PGLs usually do not.This study focused on sympathetic PGL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Functional Consequences of a SDHB Gene Mutation in an Apparently Sporadic Pheochromocytoma
Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Kerlan, V., Plouin, P.-F., Rötig, A., & Jeunemaitre, X. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020525 · Cited by 209 · cited 1×
“SDHB mutations can lead to complete loss of succinate dehydrogenase enzymatic activity in malignant PGL, with up-regulation of hypoxic-angiogenetic responsive genes (39).”
Background
Research works printed but not linked: 39
- Lenders, 2005, Phaeochromocytoma., Lancet, 366, 665, 10.1016/S0140-6736(05)67139-5 · DOI · Paper page
- Pacak, 2005, Pheochromocytoma, In: De Groot LJ, Jameson JL, eds. Textbook of endocrinology. Philadelphia: Elsevier Saunders, Inc.;, 2501
- Lenders, 2002, Biochemical diagnosis of pheochromocytoma: which test is best?, JAMA, 287, 1427, 10.1001/jama.287.11.1427 · DOI · Paper page
- Ilias, 2005, New functional imaging modalities for chromaffin tumors, neuroblastomas and ganglioneuromas., Trends Endocrinol Metab, 16, 66, 10.1016/j.tem.2005.01.007 · DOI
- Shulkin, 1999, Pheochromocytomas: imaging with 2-[fluorine-18]fluoro-2-deoxy-d-glucose PET., Radiology, 212, 35, 10.1148/radiology.212.1.r99jl3035 · DOI · Paper page
- Taniguchi, 2001, Metastases of predominantly dopamine-secreting phaeochromocytoma that did not accumulate meta-iodobenzylguanidine: imaging with whole body positron emission tomography using 18F-labelled deoxyglucose., Eur J Surg, 167, 866, 10.1080/11024150152717733 · doi:10.1080/11024150152717733
- Timmers, 2007, Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma., J Clin Oncol, 25, 2262, 10.1200/JCO.2006.09.6297 · DOI · Paper page
- Bhatia, 2008, (123)I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation., Clin Endocrinol (Oxf), 69, 181, 10.1111/j.1365-2265.2008.03256.x · DOI
- Hoegerle, 2002, Pheochromocytomas: detection with 18F DOPA whole body PET—initial results., Radiology, 222, 507, 10.1148/radiol.2222010622 · DOI · Paper page
- Hoegerle, 2003, 18F-DOPA positron emission tomography for the detection of glomus tumours., Eur J Nucl Med Mol Imaging, 30, 689, 10.1007/s00259-003-1115-3 · DOI · Paper page
- Pacak, 2001, A “pheo” lurks: novel approaches for locating occult pheochromocytoma., J Clin Endocrinol Metab, 86, 3641
- Pacak, 2001, 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma., Hypertension, 38, 6, 10.1161/01.HYP.38.1.6 · DOI · Paper page
- Harst, 2001, [(123)I]-metaiodobenzylguanidine and [(111)In]-octreotide uptake in benign and malignant pheochromocytomas., J Clin Endocrinol Metab, 86, 685
- Van Der Horst-Schrivers, 2006, Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas—experience and meta-analysis., Anticancer Res, 26, 1599
- Amar, 2005, Genetic testing in pheochromocytoma or functional paraganglioma., J Clin Oncol, 23, 8812, 10.1200/JCO.2005.03.1484 · DOI · Paper page
- Kaji, 2007, The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome., Eur J Endocrinol, 156, 483, 10.1530/EJE-06-0712 · doi:10.1530/eje-06-0712
- Linnoila, 1990, Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features., Hum Pathol, 21, 1168, 10.1016/0046-8177(90)90155-X · DOI · Paper page
- Timmers, 2007, The effects of carbidopa on uptake of 6–18F-fluoro-l-DOPA in PET of pheochromocytoma and extraadrenal abdominal paraganglioma., J Nucl Med, 48, 1599, 10.2967/jnumed.107.042721 · DOI
- Eisenhofer, 2001, The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines., Pharmacol Ther, 91, 35, 10.1016/S0163-7258(01)00144-9 · DOI · Paper page
- Pearse, 1969, The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept., J Histochem Cytochem, 17, 303, 10.1177/17.5.303 · DOI · Paper page
- Belhocine, 2006, 18FDG PET in oncology: the best and the worst, Int J Oncol, 28, 1249
- Pauwels, 2000, Positron-emission tomography with [18F]fluorodeoxyglucose. Part I. Biochemical uptake mechanism and its implication for clinical studies., J Cancer Res Clin Oncol, 126, 549, 10.1007/PL00008465 · DOI · Paper page
- Lynn, 1985, Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy., Radiology, 155, 789, 10.1148/radiology.155.3.4001380 · DOI
- Becherer, 2004, Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET., J Nucl Med, 45, 1161
- Hoegerle, 2001, Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors., Radiology, 220, 373, 10.1148/radiology.220.2.r01au25373 · DOI · Paper page
- Nanni, 2006, 18F-DOPA PET/CT and neuroendocrine tumours., Eur J Nucl Med Mol Imaging, 33, 509, 10.1007/s00259-006-0079-5 · doi:10.1007/s00259-006-0079-5
- Brink, 2006, Fluorine-18 DOPA PET imaging of paraganglioma syndrome., Clin Nucl Med, 31, 39, 10.1097/01.rlu.0000191577.39458.a0 · DOI
- Imani, 2009, 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas., J Nucl Med, 50, 513, 10.2967/jnumed.108.058396 · DOI
- Fiebrich, 2009, 18F-DOPA PET is superior to conventional imaging with 123I-metaiodobenzylguanidine scintigraphy, CT, and MRI in localizing tumors causing catecholamine excess., J Clin Endocrinol Metab, 94, 3922, 10.1210/jc.2009-1054 · DOI
- Taieb, 2008, The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas., Clin Endocrinol (Oxf), 69, 580, 10.1111/j.1365-2265.2008.03257.x · DOI
- Mackenzie, 2007, The use of 18-fluoro-dihydroxyphenylalanine and 18-fluorodeoxyglucose positron emission tomography scanning in the assessment of metaiodobenzylguanidine-negative phaeochromocytoma., Eur J Endocrinol, 157, 533, 10.1530/EJE-07-0369 · DOI
- Ilias, 2003, Superiority of 6-[18F]fluorodopamine positron emission tomography versus [131I]metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma., J Clin Endocrinol Metab, 88, 4083, 10.1210/jc.2003-030235 · DOI · Paper page
- Mann, 2006, [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma., Ann Surg Oncol, 13, 187, 10.1245/ASO.2006.04.022 · DOI
- Eisenhofer, 2001, Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes., J Clin Endocrinol Metab, 86, 1999, 10.1210/jcem.86.5.7496 · DOI · Paper page
- Timmers, 2007, Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas., J Clin Endocrinol Metab, 92, 779, 10.1210/jc.2006-2315 · DOI · Paper page
- Huynh, 2005, Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2., Eur J Endocrinol, 153, 551, 10.1530/eje.1.01987 · DOI
- Taieb, 2009, 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?, J Nucl Med, 50, 711, 10.2967/jnumed.108.060731 · DOI
- Ilias, 2008, Comparison of 6–18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma., J Nucl Med, 49, 1613, 10.2967/jnumed.108.052373 · DOI
- Fanti, 2008, Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET., Biomed Pharmacother, 62, 667, 10.1016/j.biopha.2008.01.010 · DOI
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationFassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Fassnacht, M., Tsagarakis, S., Terzolo, M., Tabarin, A., Sahdev, A., Newell-Price, J., Pelsma, I., Marina, L., Lorenz, K., Bancos, I., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad066 · Cited by 786
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Paraganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez-Roqueplo, A.-P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 490
Metadata
- Authors
- Timmers, H. J. L. M., Chen, C. C., Carrasquillo, J. A., Whatley, M., Ling, A., Havekes, B., Eisenhofer, G., Martiniova, L., Adams, K. T., & Pacak, K.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-12-01
- Volume
- 94
- Issue
- 12
- Pages
- 4757-4767
- ISSN
- 0021-972X
- 1945-7197
- Cited by
- 348
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.